With respect to the actionable gene analysis, our approach may underestimate the number of potentially druggable genes, but the fact that it readily identifies many well-established actionable gene, cancer combinations, such as, for instance, HER2 amplification in breast and gastric cancer [7, 8], indicates its validity. This evidence concerns the gene ERBB2 and gastric cancer.